BioGaia
ISIN: SE0017769995 | Ticker: BIOG | LEI: 549300UBUJOY2L7TT361
Country: Sweden
BioGaia is an innovative Swedish health care company and a world leader in probiotics. The company has more than 20 years experience in the field of probiotics that promote people’s health. BioGaia's products combine the well researched probiotic bacteria Lactobacillus reuteri and top of the line engineering to develop unique packaging solutions that make it possible to create probiotic products that match consumer needs. The class B share of BioGaia is quoted on the Mid Cap list of the Nordic Exchange Stockholm.
Year founded1990
Served areaWorldwide
HeadquartersKungsbroplan 3, 11227 Stockholm – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 1,913,282,000.00 | 2,128,054,000.00 | 2,213,966,000.00 |
| Noncurrent Assets | N/A | 223,705,000.00 | 375,977,000.00 | 416,485,000.00 |
| Property Plant And Equipment | N/A | 133,904,000.00 | 138,555,000.00 | 144,168,000.00 |
| Goodwill | N/A | 5,300,000.00 | 149,227,000.00 | 171,517,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 50,322,000.00 | 48,086,000.00 | 46,075,000.00 |
| Deferred Tax Assets | N/A | 5,279,000.00 | 2,757,000.00 | 15,325,000.00 |
| Other Noncurrent Financial Assets | N/A | 0.00 | 22,229,000.00 | 25,793,000.00 |
| Noncurrent Noncash Assets Pledged As Collateral For Which Transferee Has Right By Contract Or Custom To Sell Or Repledge Collateral | N/A | 39,000.00 | 43,000.00 | 50,000.00 |
| Current Assets | N/A | 1,689,577,000.00 | 1,752,077,000.00 | 1,797,481,000.00 |
| Inventories | N/A | 72,277,000.00 | 102,737,000.00 | 142,838,000.00 |
| Current Trade Receivables | N/A | 98,511,000.00 | 118,588,000.00 | 130,703,000.00 |
| Current Prepaid Expenses | N/A | N/A | 9,768,000.00 | 16,841,000.00 |
| Other Current Receivables | N/A | 41,538,000.00 | 36,304,000.00 | 18,733,000.00 |
| Cash and cash equivalents | 213,831,000.00 | 1,467,883,000.00 | 1,484,680,000.00 | 1,488,366,000.00 |
| Equity And Liabilities | N/A | 1,913,282,000.00 | 2,128,054,000.00 | 2,213,966,000.00 |
| Equity | 507,874,000.00 | 1,746,245,000.00 | 1,877,367,000.00 | 1,972,418,000.00 |
| Issued Capital | N/A | 20,196,000.00 | 20,196,000.00 | 20,196,000.00 |
| Additional Paidin Capital | N/A | 1,149,483,000.00 | 1,154,008,000.00 | 1,153,794,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 1,746,243,000.00 | 1,877,365,000.00 | 1,972,416,000.00 |
| Noncontrolling Interests | N/A | 2,000.00 | 2,000.00 | 2,000.00 |
| Liabilities | N/A | 167,037,000.00 | 250,687,000.00 | 241,548,000.00 |
| Noncurrent Liabilities | N/A | 31,975,000.00 | 123,733,000.00 | 76,557,000.00 |
| Deferred Tax Liabilities | N/A | 11,312,000.00 | 14,240,000.00 | 12,552,000.00 |
| Other Noncurrent Liabilities | N/A | 20,663,000.00 | 109,493,000.00 | 64,005,000.00 |
| Current Liabilities | N/A | 135,062,000.00 | 126,954,000.00 | 164,991,000.00 |
| Trade And Other Current Payables | N/A | 48,046,000.00 | 42,313,000.00 | 32,050,000.00 |
| Current Advances | N/A | 11,184,000.00 | 2,815,000.00 | 9,171,000.00 |
| Current Tax Liabilities Current | N/A | 1,170,000.00 | 4,479,000.00 | 22,715,000.00 |
| Other Current Liabilities | N/A | 25,939,000.00 | 20,948,000.00 | 23,110,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 747,077,000.00 | 785,110,000.00 | 1,103,957,000.00 |
| Other Income | 1,084,000.00 | 11,604,000.00 | 27,489,000.00 |
| Profit Loss From Operating Activities | 228,150,000.00 | 253,737,000.00 | 361,459,000.00 |
| Finance Income | 155,000.00 | 107,000.00 | 91,540,000.00 |
| Finance Costs | 722,000.00 | 1,132,000.00 | 5,386,000.00 |
| Profit Loss Before Tax | 227,583,000.00 | 252,712,000.00 | 447,613,000.00 |
| Income Tax Expense Continuing Operations | 47,853,000.00 | 56,439,000.00 | 73,840,000.00 |
| Profit (loss) | 179,730,000.00 | 196,273,000.00 | 373,773,000.00 |
| Profit Loss Attributable To Owners Of Parent | 179,730,000.00 | 196,273,000.00 | 373,773,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 179,730,000.00 | 196,273,000.00 | 373,773,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -2,347,000.00 | 9,822,000.00 | -34,125,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | 47,043,000.00 | -17,965,000.00 | -12,403,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 19,798,000.00 | -6,151,000.00 | -12,369,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | -15,471,000.00 | 12,146,000.00 | 54,256,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 20,530,000.00 | 27,241,000.00 | 23,890,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | -4,876,000.00 | 2,403,000.00 | 0.00 |
| Other Adjustments For Noncash Items | N/A | 1,167,000.00 | -2,356,000.00 | -9,103,000.00 |
| Cash Flows From Used In Operations | N/A | 244,971,000.00 | 281,025,000.00 | 376,246,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 803,000.00 | 1,132,000.00 | 5,386,000.00 |
| Interest Received Classified As Operating Activities | N/A | 157,000.00 | 64,000.00 | 7,634,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 72,092,000.00 | 55,934,000.00 | 54,910,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 221,256,000.00 | 221,875,000.00 | 318,943,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 | 98,359,000.00 | 0.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 0.00 | 22,229,000.00 | 225,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 16,075,000.00 | 6,379,000.00 | 17,916,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -16,075,000.00 | -126,967,000.00 | -18,141,000.00 |
| Proceeds From Issuing Shares | N/A | 1,126,840,000.00 | 4,525,000.00 | -214,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 0.00 | 7,174,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 7,632,000.00 | 7,527,000.00 | 9,143,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 65,012,000.00 | 68,870,000.00 | 301,331,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | -2,800,000.00 | -2,800,000.00 | -2,900,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 1,051,396,000.00 | -81,846,000.00 | -313,588,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 1,256,577,000.00 | 13,062,000.00 | -12,786,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -2,525,000.00 | 3,735,000.00 | 16,472,000.00 |
| Cash and cash equivalents | 213,831,000.00 | 1,467,883,000.00 | 1,484,680,000.00 | 1,488,366,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 02.08.23 | Anthon Jahreskog | Other | Buy | SEK 51,515.10 |
| 02.08.23 | Anthon Jahreskog | Other | Buy | SEK 18,083.00 |
SE0017769995
LEI549300UBUJOY2L7TT361
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.